BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 38743676)

  • 1. Proteomic, single-cell and bulk transcriptomic analysis of plasma and tumor tissues unveil core proteins in response to anti-PD-L1 immunotherapy in triple negative breast cancer.
    Li Y; Yue L; Zhang S; Wang X; Zhu YN; Liu J; Ren H; Jiang W; Wang J; Zhang Z; Liu T
    Comput Biol Med; 2024 Jun; 176():108537. PubMed ID: 38744008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring novel immunotherapy biomarker candidates induced by cancer deformation.
    Kim SM; Park N; Park HB; Lee J; Chun C; Kim KH; Choi JS; Kim HJ; Choi S; Lee JH
    PLoS One; 2024; 19(5):e0303433. PubMed ID: 38743676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care.
    Xiao Y; Li ZZ; Zhong NN; Cao LM; Liu B; Bu LL
    Transl Oncol; 2023 Dec; 38():101794. PubMed ID: 37820473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy.
    Dal Collo G; Takam Kamga P
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in immunotherapy for triple-negative breast cancer.
    Liu Y; Hu Y; Xue J; Li J; Yi J; Bu J; Zhang Z; Qiu P; Gu X
    Mol Cancer; 2023 Sep; 22(1):145. PubMed ID: 37660039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The deformation of cancer cells through narrow micropores holds the potential to regulate genes that impact cancer malignancy.
    Choi JS; Lee SH; Park HB; Chun C; Kim Y; Kim KH; Weon BM; Kim DH; Kim HJ; Lee JH
    Lab Chip; 2023 Aug; 23(16):3628-3638. PubMed ID: 37448298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms.
    Wang B; Han Y; Zhang Y; Zhao Q; Wang H; Wei J; Meng L; Xin Y; Jiang X
    Cell Biosci; 2023 Jun; 13(1):120. PubMed ID: 37386520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tackling of Immunorefractory Tumors by Targeting Alternative Immune Checkpoints.
    Dulal D; Boring A; Terrero D; Johnson T; Tiwari AK; Raman D
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in Melanoma: Recent Advances and Future Directions.
    Knight A; Karapetyan L; Kirkwood JM
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors.
    Dutta S; Ganguly A; Chatterjee K; Spada S; Mukherjee S
    Biology (Basel); 2023 Jan; 12(2):. PubMed ID: 36829496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions:
    Tan S; Day D; Nicholls SJ; Segelov E
    JACC CardioOncol; 2022 Dec; 4(5):579-597. PubMed ID: 36636451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome.
    Li L; Zhang F; Liu Z; Fan Z
    Cancers (Basel); 2023 Jan; 15(1):. PubMed ID: 36612317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards Novel Gene and Cell Therapy Approaches for Cervical Cancer.
    Polten R; Kutle I; Hachenberg J; Klapdor R; Morgan M; Schambach A
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting HER2-positive breast cancer: advances and future directions.
    Swain SM; Shastry M; Hamilton E
    Nat Rev Drug Discov; 2023 Feb; 22(2):101-126. PubMed ID: 36344672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.
    Wang Y; Zhang H; Liu C; Wang Z; Wu W; Zhang N; Zhang L; Hu J; Luo P; Zhang J; Liu Z; Peng Y; Liu Z; Tang L; Cheng Q
    J Hematol Oncol; 2022 Aug; 15(1):111. PubMed ID: 35978433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges.
    Uchimiak K; Badowska-Kozakiewicz AM; Sobiborowicz-Sadowska A; Deptała A
    Clin Med Insights Oncol; 2022; 16():11795549221099869. PubMed ID: 35721387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of biomarkers in personalized immunotherapy.
    Sankar K; Ye JC; Li Z; Zheng L; Song W; Hu-Lieskovan S
    Biomark Res; 2022 May; 10(1):32. PubMed ID: 35585623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer.
    Wang Y; Wang Y; Ren Y; Zhang Q; Yi P; Cheng C
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):542-565. PubMed ID: 35151845
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.